New ivermectin minitablets could treat scabies in infants and toddlers

NCT ID NCT06404333

Completed Disease control Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 2 trial tested oral ivermectin minitablets in 13 children aged 3 months and older weighing 5 to less than 15 kilograms who had scabies. The study aimed to check the safety, how the drug works in the body, and how well it treats the infection. Results will help decide if ivermectin can be used in this young age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ivermectin (oral minitablets)
What this could lead to: If successful, this could provide a safe and effective treatment option for scabies in very young children, expanding access to ivermectin therapy.
What could go wrong: This is a small, early-phase trial with only 13 participants, so results may not apply to all children. Safety and efficacy are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCABIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

scabies

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCABIES

Contacts and locations

Locations

Fundação de Dermatologia Tropical e Venereologia Alfredo da Matta (FUAM)

Manaus, 69065-130, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.